Subcutaneous Infusions of High-Dose Benzathine Penicillin G (SCIP) is Safe, Tolerable and Potentially Suitable for Less Frequent Dosing for Rheumatic Heart Disease Secondary Prophylaxis

J Kado,J Bennett,R Henderson,J Carapetis,S Enkel,S Salman,T Hla,L Manning,A Hort,M Page-Sharp,A Anderson,K Batty,R Hand

doi:10.1016/j.hlc.2022.06.515

Subcutaneous Infusions of High-Dose Benzathine Penicillin G (SCIP) is Safe, Tolerable and Potentially Suitable for Less Frequent Dosing for Rheumatic Heart Disease Secondary Prophylaxis

J Kado, J Bennett + Show 11 more

https://doi.org/10.1016/j.hlc.2022.06.515

Copy DOI

Journal: Heart Lung and Circulation	Publication Date: Jan 1, 2022
Citations: 1

Affiliation: Telethon Kids Institute, University of Western Australia, University of Otago, Princess Margaret Hospital for Children, Pathwest Laboratory Medicine, Fiona Stanley Hospital, WA Country Health Service, Government of Western Australia Department of Health, Curtin University, University of Auckland, Royal Perth Hospital

#Benzathine Benzylpenicillin #Programmatic Challenges + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Since 1955, the recommended strategy for rheumatic heart disease (RHD) secondary prophylaxis has been benzathine benzylpenicillin G (BPG; 1.2 MIU) injections administered intramuscularly. Due to dosing frequency, pain and programmatic challenges, adherence remains suboptimal. Our team has previously demonstrated that BPG delivered subcutaneously at a standard dose is safe, tolerable and has favourable pharmacokinetics, setting the scene for improved regimens with less frequent administration.

Full Text